Pulsenmore Ltd. (PLSM) 株式分析

企業概要

Pulsenmore Ltd. engages in the provision of self-scan ultrasound devices designed for remote clinical diagnosis and screening operations within the markets of Israel and Europe. The company specifically offers the Pulsenmore home ultrasound system, which consists of a handheld ultrasound cradle dock compatible with a patient's smartphone, alongside a mobile application for uploading diagnostic images. This business operates within the Healthcare sector, specifically the Medical Devices industry, positioning the firm to capitalize on the demand for accessible and decentralized diagnostic tools. Regarding its scale, Pulsenmore Ltd. holds a market capitalization of $23.41M and employs a workforce of 58 individuals. The combination of a market cap under $25 million and the absence of reported annual revenue indicates that the company is a micro-cap entity with limited operating scale relative to established peers in the global medical device sector. This valuation tier suggests the company is likely in a developmental or early commercialization phase where market penetration is still being established rather than generating significant revenue streams.

財務健全性

The company reports N/A for revenue and net income over the trailing twelve months, while its EBITDA stands at $-40,888,000, reflecting a significant negative earnings position before interest and taxes. The gap between the reported revenue of N/A and the substantial negative EBITDA reveals a cost structure where operating expenses and losses heavily outweigh any current revenue generation, which is typical for pre-profitability medical technology firms. The free cash flow is reported at $-19,023,376, indicating that the company is currently burning cash rather than generating liquidity from its operations. This negative free cash flow implies a lack of financial flexibility, necessitating the reliance on external capital sources such as equity financing or debt issuance to fund ongoing research, development, and commercialization efforts. In terms of profitability margins, the gross margin is 37.4%, suggesting that the company retains a substantial portion of revenue from its core device sales before accounting for operating expenses. However, the operating margin and profit margin are both 0.0%, which confirms that the company is not yet generating positive operating income or net profit from its current business activities. The company reports N/A for cash and N/A for debt on its balance sheet, but the debt-to-equity ratio is listed as 2.17, which suggests a leveraged capital structure relative to its equity base despite the lack of explicit debt figures. A current ratio of 7.98 indicates that the company possesses a high level of short-term liquidity, as its current assets are nearly eight times its current liabilities. This high current ratio implies strong short-term solvency and the ability to meet immediate financial obligations without distress. Furthermore, the return on equity is -45.9% and the return on assets is -19.0%, revealing that management effectiveness in generating returns for shareholders and asset holders is currently negative. These negative return metrics highlight that the company is not yet efficiently utilizing its capital base to generate value, a common characteristic of early-stage biotechnology or medical device companies.

バリュエーション評価

Pulsenmore Ltd. reports N/A for both the trailing P/E and forward P/E ratios, which implies that the company does not have positive earnings to support a traditional multiple-based valuation. The absence of a positive earnings trajectory means that these metrics are not applicable, and any valuation must rely on alternative methods such as revenue multiples or asset valuations. The price-to-book ratio and price-to-sales ratio are both reported as N/A, indicating that the market does not value the company based on its book value or sales revenue relative to its stock price in a standard manner. Similarly, the EV/EBITDA multiple is N/A, suggesting that enterprise value metrics are not currently useful for assessing the company's relative valuation due to its negative earnings profile. The stock's price metrics show a 52-week high of $10.28 and a 52-week low of $3.51, defining the historical trading range over the past year. While the exact current trading price is not explicitly listed in the provided data, the beta value of 0.23 indicates that the stock's price volatility is significantly lower than that of the broader market. This low beta suggests that the share price is less sensitive to market fluctuations, potentially offering a defensive characteristic relative to more volatile healthcare equities, although the lack of earnings makes the valuation inherently uncertain.

Growth & Income

The company reports a revenue growth rate of -8.1% year-over-year, while earnings growth is N/A due to the lack of positive net income over the trailing twelve months. The negative revenue growth indicates a contraction in sales, which is concerning for a company attempting to establish a foothold in the medical device market. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, the firm reinvests its limited resources or seeks external funding rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue expansion and an absence of dividend income, reflecting the high-risk nature of investing in a non-profitable micro-cap medical device manufacturer. This profile implies that investors are exposed to the potential for capital appreciation solely through future operational improvements and market expansion, rather than relying on current earnings or dividend distributions.